Thyroid hormone use is common in older populations, but the frequency of over-or under-replacement is debated.
T
he prevalence of thyroid function testing abnormalities in those taking thyroid hormone preparations may be high, with levels in the euthyroid range present in only 40 -60% (1, 2) . Factors that contribute to the increased risk of over-or under-replacement have not been defined, despite the clinical importance of identifying at-risk patients. We conducted an analysis of individuals taking thyroid hormone preparations who were enrolled in a population-based, longitudinal study of community dwelling individuals aged 65 yr and older. Our 1989 -1990 . The baseline visit included a medical history, physical examination, assessment of health status, and phlebotomy. The institutional review boards of all study sites and the coordinating center at the University of Washington in Seattle approved the study.
Serum TSH concentration was measured using a chemiluminescent immunometric assay (LumaTag hTSH; Nichols Institute, San Juan Capistrano, CA) with a functional sensitivity of 0.008 mU/liter on a subsample of baseline samples from 3678 individuals from the original cohort, as described previously (4) . Free T 4 concentrations were measured with a direct, monoclonal antibody assay (Amerlex-MAB; Amersham International, Buckinghamshire, UK) in individuals with serum TSH levels less than 0.10 or more than 4.50 mU/liter, for the 95% of samples with sufficient serum for this additional test.
Within this subgroup of 3678 individuals with thyroid function tests, there were 339 who were taking thyroid hormone preparations. None of these individuals had a history of thyroid cancer. For data analysis, these 339 individuals were classified into one of three groups: low TSH (TSH Յ 0.44 mU/liter), euthyroidism (TSH 0.45-4.49 mU/liter), and high TSH (TSH Ն4.5 mU/liter). We performed an additional classification in 321 individuals into five categories: overt hyperthyroidism (TSH Յ0.10 mU/ liter plus high freeT 4 ); subclinical hyperthyroidism (TSH 0.11-0.44 mU/ liter or Յ0.10 U/liter plus normal free T 4 ); euthyroidism (TSH 0.45-4.50 mU/liter); subclinical hypothyroidism (TSH 4.51-19.9 mU/liter plus normal free T 4 level); or overt hypothyroidism (TSH Ն20 mU/liter or Ͼ4.50 mU/liter plus low free T 4 ). There were 18 individuals that could not be placed into one of these categories and were excluded: two whose testing suggested recent nonadherence (low TSH and low free T 4 ), two whose testing suggested a recent dose increase (high TSH and high free T 4 ), and 14 with either TSH less than or equal to 0.10 mU/liter or elevated TSH without free T 4 level.
Statistical analysis
Baseline characteristics were summarized according to thyroid status and compared against those in the euthyroid group using a t test or 2 test. Multivariable logistical regression models comparing each abnormal TSH group (low or high) with the euthyroid group were performed in the 333 individuals who could be identified as taking either T 4 alone or a T 4 plus T 3 preparation. We included age and sex in all models, and added other covariates, if significant, in stages ͓stage 1, sociodemographical factors: body mass index, weight, smoking, race, education, and income; stage 2, comorbidities: diabetes, cancer, coronary heart disease, congestive heart failure, renal insufficiency, and lung disease; and stage 3, medications: oral steroids, ␤-blockers, lithium, and thyroid hormone preparation type͔, retaining factors that were statistically significant (P Ͻ 0.05) in the final model. All models were repeated in those using T 4 alone preparations to reflect current prescribing practices. Analyses were done using STATA version 9 (StataCorp LP, College Station, TX).
Results
Of the 3678 individuals with thyroid function testing, 339 (9.2%) were taking a thyroid hormone preparation. In these 339 thyroid hormone users, 41.0% had a low TSH, 16.2% had a high TSH, and 42.8% were in the euthyroid range. The use of preparations containing both T 4 and T 3 was common, at 26%, though their use did not differ by thyroid category. Ages were similar across all thyroid status categories, with a mean age of 72.9 yr. There were more females in the low TSH group (87.8%) than the euthyroid group (78.6%; P ϭ 0.03). Those with a low TSH had a lower weight and body mass index (65.3 vs. 72.2 kg, P Ͻ 0.001; 25.5 vs. 27.1 kg/m 2 , P ϭ 0.006), had fewer medical diagnoses (P ϭ 0.05), and were taking fewer prescription medications (P ϭ 0.02) than those in the euthyroid group.
In multivariable-adjusted models, lower weight, diabetes, and lack of renal insufficiency were independently associated with low TSH status ( Table 1 ). For every 10 kg lower weight, the likelihood of having low TSH increased by 65%. Those with diabetes were more likely and those with renal insufficiency were less likely to have low TSH levels. When we included only T 4 users in our models, results were quantitatively similar. Estrogen use was not an independent predictor of low TSH in a model in women only. Diabetes was the only statistically significant predictor of high TSH status. This association decreased in magnitude and lost statistical significance in the smaller group of those taking only T 4 preparations.
We also sought to classify further the thyroid hormone users into categories that accounted for free T 4 levels, in the 321 individuals in whom we could perform this classification (Fig. 1A) . When we examined specific preparations (Fig. 1, B and C) , the prevalence of euthyroidism was similar to the overall group.
Discussion
In a cohort study of community dwelling individuals aged 65 yr and older, we report a low prevalence of thyroid function tests in the euthyroid range in those taking thyroid hormone preparations, at only 43%. The high prevalence of over-replacement (41%) observed in our study is similar to another populationbased sample of elderly enrolled in the Framingham Heart Study during the same time frame, in which 48% of individuals taking thyroid hormone preparations had a low TSH (1), and higher than the 22% prevalence reported in a community health fair and the 5% prevalence in a study of an endocrine clinic population (2, 5). In our study, participants were unaware that thyroid function tests were being performed, unlike the latter two studies. In the study of the endocrine clinic population, inadequately controlled patients demonstrated a higher age at diagnosis, consistent with the higher prevalence of TSH abnormalities in our population (5) . One important consideration is that our thyroid function test data are from a study visit conducted in 1989 -1990 . It is possible that providers were less concerned about adverse sequelae of over-replacement at that time, though the concern over exacerbating underlying cardiac conditions in older people has been present in the field for many years, as has the "start low, go slow" recommendation for thyroid hormone replacement (6) . We also do not have data on the duration of treatment, and it is likely that a proportion of those who are over-replaced and under-replaced, though not all, were in a titration phase of therapy that would ultimately stabilize. It has been reported that older hypothyroid patients need approximately 25% less T 4 than younger patients (7, 8) . Not only is there a decrease in the secretion of thyroid hormone with increasing age (9, 10) , but the half-life of T 4 also increases with age, with a mean half-life of 6.7 d for adults aged 18 -27 yr of age, and approximately 9 d for those aged 65 yr and older (9) . Together, these data suggest that older individuals should be initiated on lower doses of T 4 replacement and that a longer duration may be required between dose titrations. Furthermore, continued monitoring is necessary to assess for decreasing thyroid hormone requirements over time. In one British study, physicians failed to adjust the T 4 dose in 89% of those with low TSH levels (11) .
We sought to identify characteristics of individuals whose TSH levels were not at goal, by examining a series of demographical and health factors that could be related to poor adherence or altered thyroid hormone requirements. A disproportionate number of women was in the low TSH group compared with the euthyroid group. Our data suggest that this difference is due to the lower weight of women because sex was no longer associated with low TSH after adjusting for weight. In this crosssectional analysis, we cannot determine whether the low weight is a contributor to low TSH levels or a result of over-replacement with thyroid hormone (accidental or intentional), though there are data to support weight-based dosing of thyroid hormone replacement (7, 12, 13) .
There was no association of altered TSH levels with polypharmacy or increased medical comorbidities that could alter thyroid hormone metabolism. In fact, the low TSH group had fewer medical diseases and less prescription medication use, though this effect disappeared in multivariable analyses. When we examined the association between individual diseases and low TSH, those with renal insufficiency were less likely to be in the low TSH group. These data suggest that there is equal or better monitoring of thyroid hormone replacement in those with chronic diseases and no effect of polypharmacy on the ability of older individuals to be able to adhere to thyroid medication daily dosing. The one exception was diabetes. In our study, both low and high TSH levels in older individuals taking thyroid hormone preparations were associated with an increased prevalence of diabetes. This suggests difficulty in managing thyroid hormone replacement in the setting of diabetes, rather than both decreased and increased dose requirements in the diabetic population. Alternatively, in the setting of multiple comparisons, this could be a spurious finding that should be verified in other populations.
A major strength of this study is the use of a large, populationbased cohort of older men and women with a wealth of data related to their health status. Our focus on the elderly targets the population most likely to experience deleterious effects from inadequate or overtreatment. In addition, we have TSH and free T 4 in a large subset of people who were not presenting for evaluation of thyroid disorders. However, our analyses are cross- sectional in nature and limit causal inference. We do not have information on the reason for thyroid hormone prescription or duration of therapy, and our subcategorization of overt and subclinical hyperthyroidism is limited by a lack of T 3 levels.
Clinical implications
Thyroid function testing abnormalities are common in elderly men and women taking thyroid hormone replacement medication. Our data support the recommendation that older individuals taking thyroid hormone preparations, especially those of lower weight or with diabetes, be monitored for thyroid function abnormalities. There are data to support acting on low TSH levels, given cardiac and skeletal effects from thyroid hormone excess that could be particularly deleterious in the elderly (1, 4, 14, 15) . The prevalence of older people taking thyroid hormone replacement who have TSH levels above 4.5 mU/liter is lower, and may be of lesser consequence, given the large proportion of older individuals without thyroid disease who have TSH levels in the 6 -8 mU/liter range (16) and data to suggest no adverse sequelae from mild TSH elevations in older people (4, 17) .
